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suppressing anti-HBs-producing B-lymphocytes.
Alternatively, a stronger anti-HBV humoral
immune response, as indicated by the presence
of anti-HBs antibodies, might in part suppress
HCV replication [13]. Heterologous immunity
and viral interactions are much more frequent
than previously thought, and cross-reactivity
between influenza A virus and HCV determin-
ant-specific cytotoxic T-cells has been described
[14]. The potential clinical relevance of viral
co-infections has been emphasised by reports on
the improved survival of HIV-positive patients
who are co-infected with GB virus C [15].
Future studies will be needed to clarify the
detailed mechanisms by which HCV replication
suppresses anti-HBs production in anti-HBc-pos-
itive patients. Understanding the pathogenesis of
HBV–HCV co-infection is important not only for
hepatologists, but also for virologists in general,
since infection with multiple hepatitis viruses
represents a unique and clinically well defined
model to study viral interactions and heterolo-
gous immunity in humans.
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A B S T R A C T
Resistance to fluoroquinolones has increased
markedly since their introduction. Mechanisms
of resistance to any antibiotic class might play a
role in resistance to an unrelated antibiotic class.
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This study evaluated the relationship between
extended-spectrum b-lactamase (ESBL) produc-
tion and ciprofloxacin resistance in Escherichia
coli and Klebsiella pneumoniae strains isolated
as causative agents of urinary tract infection.
ESBL-producing strains were significantly more
frequent among ciprofloxacin-resistant E. coli
strains than among ciprofloxacin-susceptible
E. coli strains (p ¼ 0.015), but the difference
was not significant among K. pneumoniae strains
(p ¼ 0.276).
Keywords b-Lactamase, ciprofloxacin, Escherichia
coli, extended-spectrum b-lactamases, Klebsiella
pneumoniae, resistance
Original Submission: 6 May 2002; Revised
Submission: 12 September 2002; Accepted: 15
October 2002
Clin Microbiol Infect 2004; 10; 72–75
Fluoroquinolones are potent antimicrobial agents
used for the treatment of a wide variety of
community-acquired and nosocomial infections.
However, resistance to fluoroquinolones has
increased significantly since their introduction in
the late 1980s [1,2]. The mechanisms of fluoroqu-
inolone resistance involve chromosomal muta-
tions and decreased cellular accumulation [3].
Extended-spectrum b-lactamases (ESBLs) con-
fer resistance to newer b-lactam agents possessing
an oxyimino group, such as ceftazidime, ceftriax-
one, cefotaxime and aztreonam. The genes enco-
ding ESBL production may be chromosomal or
plasmid-mediated, and it is well-known that
plasmids carrying genes encoding ESBLs may
also carry genes encoding resistance to many of
the aminoglycosides and trimethoprim–sulpha-
methoxazole [4]. In this study, the relationship
between ESBL production and ciprofloxacin
resistance was investigated in Escherichia coli and
Klebsiella pneumoniae strains isolated as causative
agents of urinary tract infection.
In total, 258 E. coli and 50 K. pneumoniae strains
isolated from January to June 2001 from urine
samples of outpatients with community-acquired
urinary tract infections were investigated. All the
strains were isolated from different patients and
were stored at )70 C in 10% v ⁄ v glycerol.
Susceptibility testing was performed by standard
disk diffusion tests [5]. ESBL production was
detected by a double disk synergy method [6] in
which ceftriaxone, ceftazidime and aztreonam
disks were placed 2–3 cm away from an amoxy-
cillin–clavulanate disk. A clear extension of the
edge of the inhibition zone of any of the antibi-
otics towards the disk containing clavulanate
was interpreted as positive for ESBL production.
The statistical significance of differences in ESBL
production between ciprofloxacin-susceptible and
ciprofloxacin-resistant strains was evaluated
using Fischer’s exact chi-square test.
Of the 258 E. coli strains tested, 137 (53.1%)
were ciprofloxacin-resistant. Seven (5.1%) of the
ciprofloxacin-resistant E. coli strains produced
ESBL. In contrast, none of the 121 ciprofloxacin-
susceptible E. coli strains were ESBL producers.
Of the 50 K. pneumoniae strains tested, 17 (34%)
were found to be resistant to ciprofloxacin. Five
(29.4%) of the ciprofloxacin-resistant and five
(15.1%) of the ciprofloxacin-susceptible K. pneu-
moniae strains produced ESBL.
Statistical analyses showed that the incidence of
ESBL production was significantly higher among
ciprofloxacin-resistant E. coli strains than among
ciprofloxacin-susceptible E. coli strains (p ¼ 0.015).
In contrast, the difference was not significant in
K. pneumoniae strains (p ¼ 0.276) (Table 1).
Paterson et al. [4] found that 15 (60%) of
25 ciprofloxacin-resistant K. pneumoniae strains
from patients with bacteraemia were ESBL pro-
ducers, but only 68 (16%) of 427 ciprofloxacin-
susceptible K. pneumoniae isolates produced ESBL.
In the same study, the proportion of ESBL
producers that were also ciprofloxacin-resistant
Table 1. ESBL production among
ciprofloxacin-resistant and -sensitive
E. coli and K. pneumoniae strains
ESBL+
n (%)
ESBL–
n (%)
Two-sided
significance Total
E. coli (n ¼ 258)
Ciprofloxacin-resistant 7 (5.1) 130 (94.9) p ¼ 0.015 137
Ciprofloxacin-sensitive 0 (0) 121 (100) p ¼ 0.015 121
K. pneumoniae (n ¼ 50)
Ciprofloxacin-resistant 5 (29.4) 12 (70.6) p ¼ 0.276 17
Ciprofloxacin-sensitive 5 (15.2) 28 (84.8) p ¼ 0.276 33
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was as high as 56% in Turkey, and it was
suggested that ciprofloxacin resistance in K. pneu-
moniae is closely associated with ESBL pro-
duction. In a European collaborative study [7],
ciprofloxacin resistance in ESBL producer and
non-producer E. coli and K. pneumoniae strains
isolated in 1994 and 1997 was compared; it was
shown that ciprofloxacin resistance did not
change among ESBL-producing K. pneumoniae,
but that ciprofloxacin resistance had increased
among ESBL-non-producing K. pneumoniae strains.
In Brazil, 94% of 72 ESBL-producing K. pneumo-
niae strains were found to be ciprofloxacin-
susceptible [8]. In a Turkish study of intensive
care and renal transplantation patients [9], 40% of
the E. coli strains were found to produce ESBL,
and in these strains the incidence of ciprofloxacin
resistance was as high as 56%. In contrast, 52% of
the K. pneumoniae strains were ESBL producers,
but the ciprofloxacin resistance rate was only 2%.
Several mechanisms are known to determine
resistance to fluoroquinolones in Gram-negative
bacteria, including mutations in the topoisom-
erase (II and IV) genes, and decreased accumu-
lation because of outer-membrane alterations
and ⁄ or expression of efflux pumps [3,10].
Among these mechanisms, alterations in the
GyrA subunit of DNA gyrase have a central
role in conferring high-level quinolone resistance
in Gram-negative bacteria, such as E. coli and
K. pneumoniae [10]. Sanders et al. [11] showed
that most quinolone-selected mutants were
cross-resistant only to other drugs within this
class, but certain mutants of K. pneumoniae
selected by quinolones were also less susceptible
to b-lactam antibiotics. It was thought that this
unusual pattern of multiple drug resistance
might be associated with changes in outer-
membrane proteins. However, it is well-known
that the multiple antibiotic resistance (mar)
locus in many Gram-negative bacteria, especially
E. coli, is responsible for resistance to many
unrelated antibiotic classes [12]. Mutations in the
mar locus or outer-membrane protein alterations
may be potential explanations for the ciprofloxa-
cin resistance observed in ESBL-producing E. coli
strains.
It is generally considered that fluoroquinolone
resistance is chromosomally-mediated [10]. How-
ever, plasmid-mediated ciprofloxacin resistance
in E. coli and K. pneumoniae has now been
reported [13]. The plasmid provided only low-
level ciprofloxacin resistance, but it facilitated
high-level resistance when the organism pos-
sessed other properties such as porin deficien-
cies.
In the present study, it was shown that all
the ESBL-producing E. coli strains were also
ciprofloxacin-resistant, and that this relationship
was statistically significant. However, there was
no such relationship between ESBL production
and ciprofloxacin resistance in K. pneumoniae
strains, although it should be noted that fewer
Klebsiella strains than E. coli strains were studied.
This could be a limitation to the detection of a
statistically significant difference. There may be
other possible explanations for the coexistence of
resistance to b-lactams and quinolones in Gram-
negative bacteria. For example, bacteria that are
able to acquire the ability to produce ESBL can be
selected by intensive quinolone use. Further
epidemiological and molecular studies are nee-
ded for an understanding of the mechanism(s)
underlying the selection of cross-resistance.
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A B S T R A C T
Susceptibility data for 10 049 Escherichia coli iso-
lates derived from community-acquired urinary
tract infections in Greece during the period January
2000 to June 2002 indicated 8.1% resistance to
nalidixic acid and 36% resistance to ciprofloxacin.
In a sample of 170 E. coli isolates, mutations in gyrA
(25 isolates) and parC (15 isolates) were consistent
with the levels of resistance to quinolones. Previous
exposure to quinolones and underlying chronic
disease were independent risk factors for infection
by quinolone-resistant E. coli strains.
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Intensive use of quinolones in the treatment of
common infections in humans and animals has
led to the spread of resistant microorganisms.
Quinolone resistance in Escherichia coli is mainly
caused by point mutations in the gyrA and parC
genes [1,2]. Such mutants are frequently encoun-
tered in hospitals worldwide. There are also
studies reporting the spread of quinolone-resist-
ant E. coli (QREC) strains in the community [3,4].
Susceptibility data from Greece have indicated a
relatively high incidence of quinolone resistance
among E. coli strains derived from hospital-
acquired urinary tract infections (UTIs) [5]. In
this study, the frequency of QREC isolates caus-
ing community-acquired UTIs in Greece was
estimated. The chromosomal mutations associ-
ated with quinolone resistance in a sample of such
isolates and the risk factors associated with
infection by QREC were also studied.
The frequency of QREC strains isolated from
community-acquired UTIs in 34 hospitals in
Greece during January 2000 to August 2002 was
calculated from the data collected by the National
Surveillance System for Antimicrobial Resistance
with the aid of WHONET software [6]. In order to
further study the epidemiological and biological
characteristics of resistance to quinolones, E. coli
strains were collected consecutively (March to
December 2000) from UTI outpatients at Laikon
teaching hospital in Athens. This is one of the
largest institutions participating in the National
Surveillance System for Antimicrobial Resistance,
with an active internal medicine outpatient clinic
serving a large catchment area that could be
considered representative of Athens. Patient data,
including demographics, underlying disease,
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